Initiating Coverage on Society Pass (SOPA).

Institutional Analyst: Society Pass (Nasdaq: SOPA) - Acquiring and Incubating Startups in the Heart of the Asian Silicon Valley

Society Pass (SOPA) Research Reports

RESEARCH REPORT ARCHIVE December 27th, 2023. Litchfield Hills Research - $4.00 Price Target.

Smart For Life (SMFL) $0.37 Announces Initiation of Equity Analyst Coverage by Dawson James...

Initiates with “Buy” recommendation and $8 price target. MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Smart for Life,...

Report: Kerrisdale Capital on Up Fintech Holding (TIGR).

The Robinhood of China? If They Liked it at $18, They've got to Love it at $4.00!

Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...

New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Revive Therapeutics

Revive Therapeutics (RVVTF, RVV): Updates and News Archive.

Recent Headlines (See FDA Filing Submission at Bottom) LIVE QUOTE
CPRE Networks

Adding VYRE Network (CAPV) to the Watch List.

Look What We Found. Our First Internet Play in Ages, And It's a Doozy. We would categorize this...
omniq

OMNIQ (OMQS) Graduates to NASDAQ. And Three Wall Street Research Reports Follow.

Wall Street Brokerage Price Target Estimates of $15 - $18 Per Share. Without disrupting legacy sales - CEO Shai...
Ehave, Psychedelic Stock Review

Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company

WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE What exactly is a favorite? First...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE

Latest article

We’re in Tampa for the Kentucky Derby.

GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!